Addex Therapeutics Debt 2024

Addex Therapeutics Aktienanalyse

What does Addex Therapeutics do?

Addex Therapeutics Ltd is a biotechnology company focused on the discovery and development of novel oral drugs. The company was founded in Geneva, Switzerland in 2002 and has made significant progress in researching drug candidates for various conditions such as schizophrenia, ADHD, migraines, and other central nervous system disorders. Addex Therapeutics' business model is based on the development of modulating therapeutics that specifically influence cellular signaling pathways. The company utilizes the proven AMC platform (Addex Modulation Cloning) to quickly and efficiently identify and validate specific receptor projects. Additionally, the company has a wide range of research and development programs, from preclinical to clinical study phases. Addex Therapeutics Ltd specializes in three therapeutic areas: neurological, immunological, and anti-inflammatory diseases. Within these areas, the company develops various drugs that specifically target certain receptors and provide help and relief for various conditions. One of Addex's most significant medical projects currently is the ADX71149 drug candidate for the treatment of schizophrenia and autism. Addex Therapeutics Ltd's products include a variety of neuromodulators and other drug candidates. The company has filed numerous international patents and maintains a high standard in the pharmaceutical development industry. The key product candidates are: - ADX10059: A new drug used in the treatment of migraines and dizziness. ADX10059 is a P2X3 receptor antagonist that can help suppress the transmission of pain signals in the central nervous system. - ADX88178: A drug candidate targeting the GABA-B receptor. This receptor is central to deep-seated pain and extrapyramidal side effects of classic antipsychotics. - ADX71943: A drug candidate used in the treatment of neuropsychiatric disorders such as Rett syndrome and ADHD. ADX71943 is a selective agonist of the GABA-B receptor, modulating the release of neurotransmitters in the brain. Overall, Addex Therapeutics offers an extensive product range and carries out a variety of projects in different stages of development. The company's core competency lies in modulators that can control specific receptors (neurotransmitter or hormone receptors). Addex Therapeutics Ltd is headquartered in Geneva, Switzerland, but also has branches in New York and San Francisco. The company focuses on expanding its competitiveness in the field of novel drugs and expanding its portfolio of products and international customers. Addex Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Addex Therapeutics's Debt Structure

Addex Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Addex Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Addex Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Addex Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Addex Therapeutics stock

What is the debt of Addex Therapeutics this year?

Addex Therapeutics has a debt level of 0 CHF this year.

What was the debt of Addex Therapeutics compared to the previous year?

The debt of Addex Therapeutics has increased by -100% compared to the previous year dropped.

What are the consequences of high debt for investors in Addex Therapeutics?

High debt can pose a risk for investors of Addex Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Addex Therapeutics?

Low debt means that Addex Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Addex Therapeutics affect the company?

An increase in debt of Addex Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Addex Therapeutics affect the company?

A reduction in debt of Addex Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Addex Therapeutics?

Some factors that can influence the debt of Addex Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Addex Therapeutics so important for investors?

The debts of Addex Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Addex Therapeutics take to change the debt?

To change the debt, Addex Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Addex Therapeutics pay?

Over the past 12 months, Addex Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Addex Therapeutics is expected to pay a dividend of 0 CHF.

What is the dividend yield of Addex Therapeutics?

The current dividend yield of Addex Therapeutics is .

When does Addex Therapeutics pay dividends?

Addex Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Addex Therapeutics?

Addex Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Addex Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Addex Therapeutics located?

Addex Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Addex Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Addex Therapeutics from 10/27/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 10/27/2024.

When did Addex Therapeutics pay the last dividend?

The last dividend was paid out on 10/27/2024.

What was the dividend of Addex Therapeutics in the year 2023?

In the year 2023, Addex Therapeutics distributed 0 CHF as dividends.

In which currency does Addex Therapeutics pay out the dividend?

The dividends of Addex Therapeutics are distributed in CHF.